Abstract
Introduction
Maintaining glycemic values within the target range can prevent or reduce the severity of microvascular complications of diabetes, as many studies demonstrated (UKPDS, ADVANCE, VADT), but the benefits of glycemic control are rarely achieved for macrovascular complications (heart attack, stroke) and mortality . Intensive glycemic control (1, 2, 3) increases the frequency and severity of iatrogenic hypoglycemia. It is known that, for patients with T1D, the mortality due to hypoglycemia is as high as 10% . At 25 years (4) after the publishing of the results of Diabetes
Control and Complications Trial Research
Group (DCCT), the high risk of hypoglycemia in the T1D group with intensive treatment represents a challenge to clarify the mechanisms of hypoglycemia in treated patients, identifying the most reliable predictors of hypoglycemia, and also the financial and human costs .
Euglycemic status is maintained by the balance of insulin and glucagon; this neuroendocrine counterregulation starts when levels are lower than 70 mg/dl (3.9 mmol/l). According to ADA hypoglycemia is (6) symptomatic (palpitations, tremor, hunger and sweating), and in moderate to severe hypoglycemia neuroglycopenic symptoms occur (behavioral changes, difficulty thinking, confusion, coma, and even death); sometimes hypoglycemia may be asymptomatic due to decreased sympathoadrenal responses.
These affect 30% of adults with T1D, especially when they are associated with the presence of cardiovascular autonomic n e u ro p a t h y. T h e a b s e n c e o f i n s u l i n determines a failure of glucagon release, preventing glycogenolysis from the liver and increasing the risk of severe hypoglycemia .
Severe hypoglycemia is more frequent in T1D, with severe consequences on heart rate variability (arrhythmias, death in bed), or on the brain. In type 2 diabetes, nephropathy and macrovascular complications, especially in older patients, with cancer or hepatic disorders, predict a moderate/severe hypoglycemia . (8) During the night, -sympatho adrenergic symptoms are attenuated, and hypoglycemia is often prolonged for 4-8 hours . The (9) hypoglycemia has side effects on the cardiovascular system causing instability of atheromatous plaque, platelet dysfunction, hypokalemia, and catecholamine release with arrhythmias . In addition, glycemic ( 1 0 ) fluctuations increase the risk of endothelial dysfunction and the cardiovascular risk , (11) coronary and carotid atherosclerosis in T2D
patients
. A recent study demonstrated the (12, 13) impact of daily glucose variability, and also in successive days, on oxidative stress . The (14) risk of progression of diabetic retinopathy and cerebral atrophy with cognitive decline caused by glucose fluctuations is well known . (15) HbA1c is a measure for the median glycemic level, but is not adequate to identify h y p o g l y c e m i a a n d p o s t p r a n d i a l hyperglycemia. The goal of 7% for HbA1c is not a good indicator of the absence of glycemic excursions . Kilpatrick . (16) et al demonstrated that in DCCT the glycemic variability measured by SD (standard deviation) and MAGE are independent predictive factors for hypoglycemia . (17) 
Material and methods
This study analyzed data from 74 adults with Hypoglycemia was defined by a glycemic value <70 mg/dl. Our data includes the day with highest variability. In this study the p a r a m e t e r s a n a l y z e d w e re : H b A 1 c , 
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with HbA1c, duration of the disease and age in either type 2 diabetes or in type 1 diabetes (Table 2 ). In patients with type 1 diabetes, severe hypoglycemia is more frequent in patients with a long duration of diabetes.
Discussion
For cardiovascular complications in type 2 diabetes, glucose fluctuations (hypo-/hyperglycemia) have a stronger impact than constant hyperglycemia , and also increase (12) inflammation with endothelial dysfunction in diabetic adolescents . (18) Hypoglycemic events were reported by 24% to 60% patients with diabetes, three times more frequently in T1D and T2D with a long duration, on average 0.35 events/ year/ patient . (19) In this study we recorded a higher number of h y p o g l y c e m i c e v e n t s t h a n i n o t h e r prospective studies because we investigated Our study has some limitations due to errors of self-monitoring and device calibration. It is known that the difference between plasma glucose and interstitial glucose is <6% . If (21) we introduced the 4 capillary glucose m e a s u re d p re p r a n d i a l l y o r 2 h o u r s p o s t p r a n d i a l l y , w e h a d a n o p t i m a l calibration . We will discuss the possible (22) m e c h a n i s m s w h i c h m a y ex p l a i n t h e association between the type of basal insulin and the hypoglycemic events. The impact of rapid human insulin on the risk for nocturnal hypoglycemia was demonstrated and in (22) this analysis the percentage of patients with T1D treated with insulin glargine U100 is higher than of those treated with insulin detemir. The retrospective or real-time CGM f o r p a t i e n t s w i t h t r e a t m e n t w i t h hypoglycemic risk, comorbidities, older and also to assess the action of new drugs . (23, 24) Silent hypoglycemia is also a manifestation 
Conclusions
Nocturnal and asymptomatic diurnal hypoglycemia is more frequent and severe in defining the treatment modality of older p a t i e n t s w i t h T 1 D a n d T 2 D w i t h comorbidities.
